PROFOUND MEDICAL CORP. Net Income (Loss) Available to Common Stockholders, Diluted
PROFOUND MEDICAL CORP. (PROF) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$9.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- PROFOUND MEDICAL CORP. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$9.54M.
- PROFOUND MEDICAL CORP. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$7.05M.
- PROFOUND MEDICAL CORP. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $76.97M, a 51.85% increase year-over-year.
- PROFOUND MEDICAL CORP. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$7.98M.
- PROFOUND MEDICAL CORP. net income (loss) available to common stockholders, diluted for fiscal 2025 was $42.57M, a 53.04% increase from fiscal 2024.
- PROFOUND MEDICAL CORP. net income (loss) available to common stockholders, diluted for fiscal 2024 was $27.82M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.54M 10-Q · filed 2026-08-06 | -$16.59M 10-Q · filed 2026-08-06 | $60.37M derived: sum of 3 quarters · filed 2026-08-06 | $52.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$7.05M 10-Q · filed 2026-05-07 | $69.91M derived: sum of 2 quarters · filed 2026-05-07 | $61.94M derived: sum of 3 quarters · filed 2026-05-07 | $46.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $76.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $68.99M derived: sum of 2 quarters · filed 2026-03-05 | $53.29M derived: sum of 3 quarters · filed 2026-08-06 | $42.57M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$7.98M 10-Q · filed 2025-11-13 | -$23.67M derived: sum of 2 quarters · filed 2026-08-06 | -$34.40M 10-Q · filed 2025-11-13 | $16.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$15.70M 10-Q · filed 2026-08-06 | -$26.42M 10-Q · filed 2026-08-06 | $24.27M derived: sum of 3 quarters · filed 2026-08-06 | $14.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$10.72M 10-Q · filed 2026-05-07 | $39.96M derived: sum of 2 quarters · filed 2026-05-07 | $30.60M derived: sum of 3 quarters · filed 2026-05-07 | $23.68M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $50.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $41.32M derived: sum of 2 quarters · filed 2026-03-05 | $34.40M derived: sum of 3 quarters · filed 2026-03-05 | $27.82M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$9.37M 10-Q · filed 2025-11-13 | -$16.28M derived: sum of 2 quarters · filed 2025-11-13 | -$22.87M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$6.92M 10-Q · filed 2025-08-14 | -$13.50M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | -$6.58M 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |